论文部分内容阅读
目的 探讨蛋白激酶A(PKA)RIαmRNA表达与肺癌临床病理特征的相关性。方法 采用逆转录 聚合酶链反应 (RT PCR)的方法 ,检测 5 4例肺癌患者癌组织及相应远端正常组织中PKARIαmRNA的表达水平。结果 (1)PKARIαmRNA在肺癌组织中的表达 (6 6 .7% )明显高于相应远端正常组织 (2 0 .4 % ,P <0 .0 1)。 (2 )PKARIαmRNA表达与肺癌TNM分期明显相关 (P <0 .0 1) ,临床分期级别越高 ,PKARIαmRNA表达越高。 (3)淋巴结转移阳性者的PKARIαmRNA表达水平 ,明显高于淋巴结转移阴性者 (P <0 .0 1)。 (4 )PKARIαmRNA表达与肿瘤组织学类型、分化及肿瘤大小无相关性(P >0 .0 5 )。结论 PKARIαmRNA在肺癌组织中过表达 ,提示PKARIαmRNA在肺癌的发生、发展、转移和预后中起重要作用
Objective To investigate the relationship between protein kinase A (PKA) RIα mRNA expression and clinicopathological features of lung cancer. Methods Reverse transcription polymerase chain reaction (RT PCR) was used to detect the expression of PKARα mRNA in 54 cases of lung cancer and corresponding normal tissues. Results (1) The expression of PKAR1α mRNA in lung cancer tissues (66.7%) was significantly higher than that in the corresponding normal tissues (20.4%, P <0.01). (2) The expression of PKARIαmRNA was significantly correlated with the TNM staging of lung cancer (P <0.01). The higher the clinical stage was, the higher the PKARIαmRNA expression was. (3) The expression of PKAR1αmRNA in lymph node positive patients was significantly higher than that in lymph node negative patients (P <0.01). (4) There was no correlation between the expression of PKAR1αmRNA and tumor histological type, differentiation and tumor size (P> 0.05). Conclusion PKARIα mRNA overexpression in lung cancer suggests that PKARα mRNA may play an important role in the development, progression, metastasis and prognosis of lung cancer